Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Cash from Financing Activities: 2013-2024

Historic Cash from Financing Activities for Seres Therapeutics (MCRB) over the last 12 years, with Dec 2024 value amounting to -$90.4 million.

  • Seres Therapeutics' Cash from Financing Activities rose 100.06% to $61,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$107.9 million, marking a year-over-year decrease of 28.08%. This contributed to the annual value of -$90.4 million for FY2024, which is 226.03% down from last year.
  • Seres Therapeutics' Cash from Financing Activities amounted to -$90.4 million in FY2024, which was down 226.03% from $71.7 million recorded in FY2023.
  • Seres Therapeutics' Cash from Financing Activities' 5-year high stood at $303.4 million during FY2020, with a 5-year trough of -$90.4 million in FY2024.
  • In the last 3 years, Seres Therapeutics' Cash from Financing Activities had a median value of $71.7 million in 2023 and averaged $37.0 million.
  • Per our database at Business Quant, Seres Therapeutics' Cash from Financing Activities spiked by 10,901.87% in 2022 and then slumped by 226.03% in 2024.
  • Yearly analysis of 5 years shows Seres Therapeutics' Cash from Financing Activities stood at $303.4 million in 2020, then plummeted by 99.61% to $1.2 million in 2021, then skyrocketed by 10,901.87% to $129.6 million in 2022, then tumbled by 44.67% to $71.7 million in 2023, then plummeted by 226.03% to -$90.4 million in 2024.